Dishman Pharmaceuticals and Chemicals is currently trading at Rs. 235.20, up by 7.25 points or 3.18% from its previous closing of Rs. 227.95 on the BSE.
The scrip opened at Rs. 236.70 and has touched a high and low of Rs. 238.35 and Rs. 234.40 respectively. So far 36,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 267.95 on 30-Sep-2016 and a 52 week low of Rs. 127.60 on 24-Jun-2016.
Last one week high and low of the scrip stood at Rs. 238.35 and Rs. 220.70 respectively. The current market cap of the company is Rs. 3,795.00 crore.
The promoters holding in the company stood at 61.40%, while Institutions and Non-Institutions held 22.95% and 15.65% respectively.
Dishman Pharmaceuticals and Chemicals has received Establishment Inspection Report (EIR) from the USFDA for its Bavla facility on February 01, 2017. Thus, the company’s facilities in Bavla, Naroda and Switzerland continue to be approved by the USFDA. The US Food and Drug Administration (USFDA) had inspected Bavla facility in July, 2016.
Dishman Pharmaceuticals and Chemicals is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. It improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in Europe and in India.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: